CSI Market
Sign In | Register

Senti Biosciences Holdings Inc (SNTI) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access SNTI quarterly Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Senti Biosciences Holdings Inc's cash-generating activities.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-61.44
Depreciation & amortization3.64
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.04
Asset Impairment Charges5.05
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation5.71
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Investment Income Nonoperating-
Operating Lease Right Of Use Asset Amortization Expense-
Fair Value Adjustment Preferred Stock Tranche Liability-
Increase Decrease In Contract With Customer Liability-
Increase Decrease In Deferred Sublease Income-0.36
Interest Income Accrued And Not Received-
Increase Decrease In Operating Lease Right Of Use Asset2.29
Gain Loss On Lease Modification Gross-
Income taxes0.04
Unrealized Gain (Loss) on Derivatives0.00
Increase (Decrease) in Accounts Receivable-0.16
Increase (Decrease) in Accounts Payable1.74
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities0.56
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.68
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.24
Discontinued operations0.00
Net Cash flow from Operating Activities-43.44
Investing Activities
Capital Expenditures-0.20
Sale of Capital Items0.01
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.18
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock11.76
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-51.82
Proceeds From Merger And Related P I P E Financing Net Of Transaction Costs-
Payment Of Deferred Offering Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents51.82
Finance Lease Principal Payments-
Net Proceeds From Grant-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities11.76
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-43.63
Total Cash Flow-31.87
4 historic quarters locked

Sign in to unlock the full Senti Biosciences Holdings Inc cash flow history.

Sign In Create Free Account

About Senti Biosciences Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-021580

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License